SCHEMBL352494

SCHEMBL352494

O=c1[c]cnc2n1CCS2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
XDH P47989 2/20 0.39
HPGD P15428 1/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18716374 0.67 ALDH1A1 (0.54) ALDH1A1RAB9ASMN1; SMN2MAPTL3MBTL1
SCHEMBL16398246 0.65
SCHEMBL15113582 0.63 ALDH1A1 (0.50) ALDH1A1RAB9ASMN1; SMN2MAPTL3MBTL1
SCHEMBL8807325 0.59 L3MBTL1 (0.59) ALDH1A1SMN1; SMN2MAPTL3MBTL1XDH
SCHEMBL16398003 0.58
SCHEMBL12012165 0.57 LMNA (0.41) ALDH1A1SMN1; SMN2MAPTXDHHPGD
SCHEMBL6947543 0.54 MAPT (0.45) ALDH1A1RAB9ASMN1; SMN2MAPTL3MBTL1
SCHEMBL17784389 0.54
SCHEMBL20112541 0.54 XDH (0.47) ALDH1A1RAB9ASMN1; SMN2MAPTXDH
SCHEMBL925818 0.53 MAPT (0.47) ALDH1A1RAB9ASMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
US-6638955-B2 Antibiotic oxazolidinone derivatives SYNGENTA LIMITED (GB) 2003-10-28 US claimed
US-20030166684-A1 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents SYNGENTA LIMITED (GB) 2003-09-04 US claimed
EP-0912561-B1 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2002-12-04 EP claimed
US-20020133022-A1 Antibiotic oxazolidinone derivatives SYNGENTA LIMITED (GB) 2002-09-19 US claimed
US-6365751-B1 ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC ZENECA LTD. (GB) 2002-04-02 US claimed
US-6110936-A A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL ZENECA LIMITED (GB) 2000-08-29 US claimed
EP-0445862-B1 N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2000-04-19 EP claimed
US-5981528-A Antibiotic oxazolidinone derivatives ZENECA LIMITED 1999-11-09 US claimed
EP-0912561-A1 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 1999-05-06 EP claimed
EP-0882042-A1 ANTIBIOTIC OXAZOLIDINONE DERIVATIVES AstraZeneca UK Limited (GB) 1998-12-09 EP claimed
WO-1997043280-A1 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS ZENECA LIMITED (GB) 1997-11-20 WO claimed
WO-1997030995-A1 ANTIBIOTIC OXAZOLIDINONE DERIVATIVES ZENECA LIMITED (GB) 1997-08-28 WO claimed
US-5262418-A Laxatives, gastrointestinal disorders TANSSEN PHARMACEUTICA N.V. (BE) 1993-11-16 US claimed
US-5185335-A Administer to mammals to stimulate gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1993-02-09 US claimed
EP-0445862-A2 N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1991-09-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ALDH1A1 2806/4885RAB9A 1714/4885SMN1; SMN2 2356/4885
US-20030166684-A1 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents CBR1, CBR3, CYP8B1 ALDH1A1 1425/4885RAB9A 1481/4885SMN1; SMN2 2599/4885
US-20020133022-A1 Antibiotic oxazolidinone derivatives OXA1L, POLN, MRPL21 ALDH1A1 2601/4885RAB9A 1247/4885SMN1; SMN2 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.